Human RANK ELISA Kit (ab277714)
Key features and details
- One-wash 90 minute protocol
- Sensitivity: 3.07 pg/ml
- Range: 15.63 pg/ml - 1000 pg/ml
- Sample type: Cell culture media, Cit plasma, EDTA Plasma, Hep Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Human RANK ELISA Kit
See all RANK kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Serum 8 4.8% Inter-assay Sample n Mean SD CV% Serum 3 5.5% -
Sample type
Serum, Cell culture media, Hep Plasma, EDTA Plasma, Cit plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
3.07 pg/ml -
Range
15.63 pg/ml - 1000 pg/ml -
Assay time
1h 30m -
Assay duration
One step assay -
Species reactivity
Reacts with: Human -
Product overview
Human RANK ELISA kit (ab277714) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Human RANK protein in human serum, plasma, and cell culture supernatant. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human RANK with 3.07 pg/mL sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells stripsA 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
-
Notes
RANK, also known as TNFRSF11A or TRANCE, is a type 1 transmembrane protein receptor and is a member of the tumor necrosis factor receptor molecular subfamily. RANK binds RANKL and plays a key role in regulation of osteogenesis and specific immunity. ab277714 recognizes the soluble extracellular fragment of RANK.
-
Platform
Pre-coated microplate (12 x 8 well strips)
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 x 96 tests 10X Human RANK Capture Antibody 1 x 600µl 10X Human RANK Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent 5BI 1 x 6ml Human RANK Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml -
Research areas
-
Function
Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells. -
Tissue specificity
Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. -
Involvement in disease
Defects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early onset deafness and loss of dentition.
Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.
Defects in TNFRSF11A are the cause of osteopetrosis autosomal recessive type 7 (OPTB7) [MIM:612301]; also called osteoclast-poor osteopetrosis with hypogammaglobulinemia. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. -
Sequence similarities
Contains 4 TNFR-Cys repeats. -
Cellular localization
Membrane. - Information by UniProt
-
Alternative names
- CD 265
- CD265
- FEO
see all -
Database links
- Entrez Gene: 8792 Human
- Omim: 603499 Human
- SwissProt: Q9Y6Q6 Human
- Unigene: 204044 Human
Images
-
SimpleStep ELISA Protocol Diagram
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
-
Example of human RANK standard curve in Sample Diluent NS. The RANK standard curve was prepared as described in Section 10.Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.
-
Interpolated concentrations of native RANK in human serum and plasma samples. The concentrations of RANK were measured in duplicates, interpolated from the RANK standard curves and corrected forUndiluted samples are as follows: serum 50%, plasma (citrate) 50%, plasma (EDTA) 50%, and plasma (heparin) 50%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean RANK concentration was determined to be 336.7 pg/mL in serum, 106.0 pg/mL in plasma (citrate), 150.9 pg/mL in plasma (EDTA), and 131.7 pg/mL in plasma (heparin).
-
Serum from ten individual healthy human male donors was measured in duplicate.Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean RANK concentration was determined to be 142.2 pg/mL with a range of 99.8 – 295.5 pg/mL.
-
Recombinant Antibody BenefitsTo learn more about the advantages of recombinant antibodies see here.
